8-K: Xilio Therapeutics Announces Pipeline Progress, Gilead Partnership, and Year-End 2023 Financials

Xilio Therapeutics reported its fourth quarter and full year 2023 financial results, highlighted by a new licensing agreement with Gilead for its XTX301 program and plans to advance its clinical pipeline.

Summary

• Xilio Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023, along with pipeline and business updates.
• The company has entered into an exclusive license agreement with Gilead for its tumor-activated IL-12 program, XTX301, receiving $43.5 million upfront, including a $30 million cash payment and a $13.5 million equity investment.
• Xilio is eligible for up to $604 million in additional contingent payments, including further equity investments, a $75 million transition fee, and milestone payments, plus tiered royalties on sales.
• The company plans to initiate a Phase 2 trial for XTX101 in combination with atezolizumab for microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024.
• Initial Phase 2 data for XTX101 in MSS CRC is expected in the fourth quarter of 2024, with additional data in the first quarter of 2025.
• Xilio is focusing its research efforts on tumor-activated bispecifics and immune cell engagers, discontinuing further investment in XTX202 as a monotherapy.
• A private placement equity financing is expected to close on April 2, 2024, raising approximately $11.3 million.
• The company is implementing a strategic portfolio prioritization and a 21% workforce reduction.
• Cash and cash equivalents were $44.7 million as of December 31, 2023, compared to $120.4 million the previous year.
• Research and development expenses were $52.1 million for the year ended December 31, 2023, down from $59.2 million in 2022.
• Net loss for the year ended December 31, 2023, was $76.4 million, compared to $88.2 million in 2022.
• Xilio anticipates its cash runway will extend into the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative developments. The Gilead partnership and pipeline advancements are positive, while the workforce reduction and cash burn are negative. Overall, the sentiment is cautiously optimistic.

Positives

• The exclusive licensing agreement with Gilead for XTX301 provides significant upfront funding and potential future revenue through milestones and royalties.
• The company is on track to initiate a Phase 2 trial for XTX101 in combination with atezolizumab in the third quarter of 2024.
• Xilio has a clear timeline for reporting initial Phase 2 data for XTX101 in MSS CRC.
• The strategic portfolio prioritization will focus resources on the most promising programs.
• The private placement provides additional funding to support operations.
• The company has reduced its operating expenses year-over-year.
• The cash runway extends into the second quarter of 2025, providing financial stability.

Negatives

• The company is discontinuing further investment in XTX202 as a monotherapy.
• A 21% workforce reduction was implemented as part of the strategic portfolio prioritization.
• Cash and cash equivalents have decreased significantly from $120.4 million to $44.7 million year-over-year.
• The company reported a net loss of $76.4 million for the year ended December 31, 2023.

Risks

• The success of the Phase 2 trial for XTX101 is subject to clinical trial risks and uncertainties.
• The company's ability to achieve future milestone payments from Gilead is contingent on the successful development and commercialization of XTX301.
• The strategic portfolio prioritization and workforce reduction may impact the company's operations and development timelines.
• The company's cash runway is dependent on the successful closing of the private placement and the receipt of the upfront payment from Gilead.
• There are risks associated with the development of novel therapies, including regulatory approvals and market acceptance.

Future Outlook

Xilio anticipates its cash runway will extend into the second quarter of 2025, and the company is focused on rapidly advancing clinical development for XTX301 and XTX101, with anticipated clinical data for each of these programs later this year. They also plan to leverage their research platform to develop tumor-activated bispecific and immune cell engager molecules.

Management Comments

• With our recently announced partnership with Gilead for XTX301, our tumor-activated IL-12, and additional financing from existing investors, we believe we are well-positioned to continue to advance our differentiated pipeline of tumor-activated I-O therapies and achieve potential near-term clinical milestones and value-drivers, said Ren Russo, Pharm.D., president and chief executive officer of Xilio.
• Looking ahead, we are focused on rapidly advancing clinical development for XTX301 and XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, with anticipated clinical data for each of these programs later this year, as well as continuing to leverage our novel research platform to design and develop tumor-activated bispecific and immune cell engager molecules.

Industry Context

The announcement reflects a trend in the immuno-oncology space towards developing tumor-activated therapies to minimize systemic side effects and improve efficacy. The partnership with Gilead highlights the value of Xilio's technology and its potential to address unmet needs in cancer treatment. The focus on bispecifics and immune cell engagers aligns with the industry's interest in next-generation immunotherapies.

Comparison to Industry Standards

• Xilio's approach of developing tumor-activated therapies is similar to other companies in the immuno-oncology space, such as BioNTech and Immatics, which are also developing targeted therapies to reduce off-target effects.
• The licensing agreement with Gilead is comparable to other deals in the biotech industry, where larger pharmaceutical companies acquire rights to promising early-stage assets.
• The reported cash runway into the second quarter of 2025 is a common metric for biotech companies, and Xilio's runway is in line with other companies of similar size and stage.
• The reduction in R&D expenses is a common strategy for biotech companies to manage cash burn, especially when prioritizing specific programs.

Stakeholder Impact

• Shareholders will be impacted by the Gilead partnership, the private placement, and the strategic portfolio prioritization.
• Employees will be impacted by the workforce reduction.
• Patients may benefit from the development of new cancer therapies.
• Creditors will be impacted by the repayment of the outstanding loan balance.

Next Steps

• Select a recommended Phase 2 dose for XTX101 in the second quarter of 2024.
• Initiate the Phase 2 portion of the trial for XTX101 in combination with atezolizumab in patients with MSS CRC in the third quarter of 2024.
• Report initial Phase 2 data for XTX101 in MSS CRC in the fourth quarter of 2024 and additional data in the first quarter of 2025.
• Report Phase 1 safety, pharmacokinetic and pharmacodynamic data for XTX301 in the fourth quarter of 2024.
• Close the private placement equity financing on April 2, 2024.
• Continue to advance clinical development for XTX301 and XTX101.
• Leverage the company's research platform to advance differentiated tumor-activated bispecific and immune cell engager molecules.

Key Dates

Keywords

immuno-oncology, tumor-activated, anti-CTLA-4, IL-12, bispecific, clinical trial, Gilead, XTX101, XTX301, cancer therapy